NOTCH3-targeted antibody drug conjugates regress tumors by inducing apoptosis in receptor cells and through transendocytosis into ligand cells

 Aberrant NOTCH3 signaling and overexpression is oncogenic, related with most cancers stem cells and drug resistance, but therapeutic concentrating on stays elusive. Right here, we develop NOTCH3-targeted antibody drug conjugates (NOTCH3-ADCs) by bioconjugation of an auristatin microtubule inhibitor via a protease cleavable linker to 2 antibodies with differential skills to inhibit signaling. The signaling inhibitory…

Read More